In a clinical trial, 120 patients received a drug, and 36 showed significant improvement. What percentage of patients responded positively?

Wed, 06 May 2026 07:35:52 +0000

**How a Drug Crushes Resistance in Early Trials—And What That 30% Response Rate Really Means** Across the U.S., clinical trials are increasingly shaping how medicine evolves—but few numbers spark as much quiet curiosity as this: in a trial where 120 patients received a new therapy, 36 showed meaningful improvement. What does that mean? At first glance, it’s a simple math question—but the real story reveals evolving standards in modern drug development. This 30% response rate isn’t just a statistic—it’s a sign of progress. Break it down: roughly one-third of participants experienced beneficial outcomes, offering a measurable window into the drug’s effectiveness. In fields like oncology and rare disease treatment, this level of success is nothing short of promising, especially when weighed against standard care outcomes. It speaks to both targeted design and biological variability among individuals. **Why This Trial Is Gaining Attention in the US**